Adicet Bio, Inc. (FRA:1IJ)

Market Cap	72.00M -10.3%
Revenue (ttm)	n/a
Net Income	-98.03M
EPS	-17.20
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	169
Open	6.72
Previous Close	7.02
Day's Range	6.72 - 6.72
52-Week Range	5.38 - 17.66
Beta	n/a
RSI	49.14
Earnings Date	Mar 6, 2026

About Adicet Bio

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company’s lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodg...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 152
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1IJ

Financial Performance

Financial numbers in USD